In prostate cancers, loss of p53 compromises p53-induced miR-143, facilitating degradation of HK2 mRNA, which is required for Pten/p53-deficiency-driven aerobic glycolysis, proliferation, transformation, and in vivo tumor growth (19). This evidence concerns the gene PTEN and neoplasm.